🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Solution for injection in pre-filled syringe

    Alphapharm Pty Ltd

    Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)

    phase 2 small molecule active

    1 trial

  2. SonoVue 8 microlitres/mL powder and solvent for dispersion for injection, CARBOPLATIN

    Pari Pharma GmbH

    recurrent primary supratentorial malignant brain tumors in children

    phase 2 small molecule active

    1 trial

  3. Stellate Ganglion Block injection with ropivicane

    United Therapeutics Europe Ltd

    Post Traumatic Stress Disorder (PTSD)

    phase 2 other completed

    1 trial

  4. Stem cell infusion

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule terminated

    1 trial

  5. Stromal-vascular fraction

    Century Therapeutics

    Knee Osteoarthritis

    phase 2 mab active

    1 trial

  6. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  7. Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept

    Regeneron UK Limited

    Thyroid Eye Disease

    phase 2 small molecule completed

    1 trial

  8. Subcutaneous injection of TAK-850

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  9. Sugammadex Injection 2mg/kg

    BRIGHT MINDS BIOSCIENCES INC.

    Anesthesia, General

    phase 2 small molecule completed

    1 trial

  10. TAK-019

    Takeda

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

  11. TAK-279 Placebo (same excipient as TAK-279), ZASOCITINIB

    Takeda

    Moderate to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  12. TAK-279 placebo (same excipient as TAK-279), ZASOCITINIB, ZASOCITINIB

    Takeda

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  13. TAK-850

    Takeda

    Influenza Infection

    phase 2 mab completed

    1 trial

  14. TAK-850 0.5 mL injection

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  15. TAK-954 Placebo

    Takeda

    Postoperative Gastrointestinal Dysfunction

    phase 2 small molecule completed

    1 trial

  16. TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  17. TAR-0520 gel matching vehicle without active ingredients, TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    EGFR inhibitor-induced folliculitis

    phase 2 small molecule active

    1 trial

  18. TD-1792

    Theravance Biopharma Ireland Umited

    Staphylococcal Skin Infection

    phase 2 small molecule completed

    1 trial

  19. TD-4208

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  20. TD-9855

    Theravance Biopharma Ireland Umited

    Attention-Deficit/Hyperactivity Disorder

    phase 2 small molecule completed

    1 trial

  21. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial

  22. TENOFOVIR ALAFENAMIDE , Sodium chloride solution 0.9%, ENTECAVIR , TENOFOVIR DISOPROXIL , JNJ-73763989

    Janssen-Cilag International N.V.

    Hepatitis B and Hepatitis D Viral Co-infection

    phase 2 small molecule active

    1 trial

  23. TEPADINA 15 mg powder for concentrate for solution for infusion, Trecondi 5 g powder for solution for infusion, Mozobil 20 mg/ml solution for injection, Trecondi 5 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded.

    Fondazione Telethon ETS

    Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene

    phase 2 small molecule active

    1 trial

  24. TETRACOSACTIDE , EP-104GI

    EUPRAXIA PHARMACEUTICALS INC.

    Eosinophilic esophagitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources